Afatinib (Giotrif®) in patients with non-small cell lung cancer (NSCLC) who are refractory to erlotinib/gefitinib and afatinib monotherapy

Grössmann N

Record Status
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.

Citation

Authors' conclusions
The combined use of afatinib and paclitaxel for this indication has been investigated in the LUX–Lung 5 trial, a randomised, open-label phase III study. Although the study shows a significant gain in median PFS, the treatment with afatinib–paclitaxel is associated with a higher expanse of AEs and relatively high costs. In addition, more data will be required due to the unexpected low number of enrolled patients and the subsequent lower power of the study.

Project page URL
http://eprints.hta.lbg.ac.at/1089/

Final publication URL
http://eprints.hta.lbg.ac.at/1089/1/DSD_HSO_Nr.59.pdf

Additional data URL
http://hta.lbg.ac.at/page/horizon-scanning-in-der-onkologie/en

Indexing Status
Subject indexing assigned by CRD

MeSH
Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines

Language Published
English

Country of organisation
Austria

English summary
An English language summary is available.

Address for correspondence
Ludwig Boltzmann Institute fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7 rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99

AccessionNumber
32016000988

Date abstract record published
14/09/2016